UBS Maintains Buy Rating on WuXi Biologics
UBS maintained its Buy rating on WuXi Biologics and its price target.
Related stories
Lufthansa CEO Says Q4 Demand Stays Robust Despite Double-Digit Fare Hikes
The CEO said demand, including premium demand, remained robust in Q4 despite a double-digit increase in ticket prices.
M impact | EQUITY | Nov 03, 2026, 09:51 AM UTC
Asiacell Communications quarterly revenue 532.91 billion dinars
M impact | EQUITY | Nov 03, 2026, 09:49 AM UTC
Saudi PIF Secures Financing Guaranteed by SACE
Saudi Arabia’s Public Investment Fund obtained financing guaranteed by Italy’s SACE, Reuters reported.
M impact | EQUITY | Nov 03, 2026, 09:49 AM UTC
Asiacell reports quarterly profit after tax of 121.05 billion dinars
M impact | EQUITY | Nov 03, 2026, 09:49 AM UTC
Hinduja Leyland Finance Plans 5.75 Billion-Rupee Bond Issue
The Indian non-bank lender plans to raise 5.75 billion rupees ($60.64 million) through two-year bonds and a reissue of 9.3% December 2032 Tier II notes. The amount includes a 3 bil
L impact | EQUITY | Nov 03, 2026, 09:48 AM UTC
LVMH Shares Hit 5-week High
LVMH shares increased to 399.55 EUR, the highest since September 2026. Over the past 4 weeks, LVMH gained 4.7%, and in the last 12 months, it decreased 34.75%.
L impact | EQUITY | Nov 03, 2026, 09:47 AM UTC